Get started
Work

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

Year: 2015
Type: article
DOI: 10.1016/s0959-8049(16)31926-8
Authors: P. Sharma, B. Escudier, D.F. McDermott, S. George, H.J. Hammers, S. Srinivas, S.S. Tykodi, J.A. Sosman, G. Procopio, E.R. Plimack, D. Castellano, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T.C. Gauler, T. Ueda, L.A. Xu, I.M. Waxman, R.J. Motzer
Institutions: The University of Texas MD Anderson Cancer Center, Institut Gustave Roussy, Dana-Farber Cancer Institute, Roswell Park Comprehensive Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Stanford Cancer Institute, University of Washington, Vanderbilt University, Fondazione IRCCS Istituto Nazionale dei Tumori, Fox Chase Cancer Center, Hospital Universitario 12 De Octubre, Western Sydney Local Health District, Aarhus University, University of Helsinki, Swansea University, University of Duisburg-Essen, Chiba Cancer Center, Bristol-Myers Squibb (United States), Memorial Sloan Kettering Cancer Center
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W2514514995
FWCI: 0.95
Cites:
Cited by: 6
Related to: 10